“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in AUD
Last close As at 25/03/2023
AUD1.32
▲ 0.02 (1.54%)
Market capitalisation
AUD369m
Paradigm Biopharmaceuticals is an Australian biotechnology company focused on the development of injectable pentosan polysulfate (iPPS). Its most advanced clinical programme is investigating the drug’s use as a potentially disease modifying treatment for knee osteoarthritis (kOA).
Knee osteoarthritis is a highly prevalent and quality-of-life impacting disease. Currently no disease modifying drugs are available for the condition, resulting in serious unmet medical needs and a potentially significant opportunity for drug developers.
Managing Director - Head of Content, Healthcare
Simon White
Director of investor relations
Forecast net debt (A$m)
N/A
Forecast gearing ratio (%)
N/A
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (9.9) | (12.6) | 17.7 |
| Relative | (4.8) | (10.7) | 24.5 |
| 52 week high/low | A$2.1/A$0.9 |
Paradigm has presented its half yearly results and accounts, reflecting an active period. This included an encouraging safety review for injectable pentosan polysulfate sodium (iPPS, Zilosul) in the pivotal Phase III trial (PARA_OA_002) for patients with knee osteoarthritis (kOA) pain. The Phase II (PARA_OA_008) biomarker trial reached its primary endpoint, positioning iPPS as a potentially disease-modifying drug. In our opinion, the initiation of the confirmatory Phase III trial (PARA_OA_003) and six-month follow-up results from the PARA_OA_008 trial represent major catalysts expected in CY23. At end-December 2022, the company had A$83.9m cash, supported by an August 2022 capital raise of A$66.0m.
| Y/E Jun | Revenue (A$m) | EBITDA (A$m) | PBT (A$m) | EPS (fd) (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2021A | 8.9 | (51.5) | (34.3) | (16.74) | N/A | N/A |
| 2022A | 0.1 | (55.7) | (39.2) | (16.87) | N/A | N/A |
| 2023E | N/A | N/A | N/A | N/A | N/A | N/A |
| 2024E | N/A | N/A | N/A | N/A | N/A | N/A |
Managing Director - Head of Content, Healthcare
Get access to the very latest content matched to your personal investment style.
